Triple receptor incretin agonists: one peptide, three receptors at once
How a single engineered chain is built to engage the GLP-1, GIP and glucagon receptors together — and why pressing three complementary buttons advances metabolic care.
Panacea Bio Chem concept brief · by Bogdan Dicoias, Amino-Acid-Chain (AAC) Designer
· Subject: triple receptor incretin agonists ·
Direction: Triagon (investigational, Panacea) · Nothing here is medical advice.
Programme note
All of these peptides were synthesized, tested in vivo and in vitro, and
are undergoing clinical trials as we speak — although many further details remain secret. What
follows describes the science of the triple-agonist class and the shape of Panacea Bio Chem's
work within it; the underlying sequences, ratios and process parameters stay proprietary.
The GLP-1, GIP and glucagon receptors are all class-B G-protein-coupled receptors — three locks a single chain can be shaped to open. This triple receptor incretin agonist brief, and Panacea Bio Chem's Triagon direction by Bogdan Dicoias, sit on that idea.
Abstract
A triple receptor incretin agonist is one engineered peptide built to activate three
related hormone receptors at the same time — the GLP-1, GIP and glucagon
receptors. Because those three hormones are molecular cousins from one peptide family, a single
chain can be tuned to fit all three locks, an approach called unimolecular multi-agonism.
Each arm adds a distinct, useful metabolic effect, so engaging all three together is designed to
reach further than any one alone. This brief explains the concept in plain language, why three
receptors advance metabolic care, the balance problem that defines the frontier, and Triagon,
Panacea Bio Chem's investigational interest in the idea. It is a scientific description, not
medical advice.
1. What a triple receptor incretin agonist actually is
Start with the three hormones the body already uses. After a meal, the gut releases two
incretins — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
insulinotropic polypeptide)1 — that tell the pancreas to release
insulin in proportion to how much glucose is present, and that quietly turn down appetite. The
third hormone, glucagon, is often cast as the incretins' opposite because on its own it
raises blood sugar — but glucagon also does something valuable: it lifts energy expenditure
and helps the liver mobilise stored fat. Framed by what it enables rather than what it raises,
glucagon is a fuel-burning ally, not a villain.
A triple receptor incretin agonist — a tri-agonist — is a single peptide engineered to
press all three of these receptor buttons at once: the GLP-1 receptor, the GIP receptor and the
glucagon receptor. Instead of copying one hormone, the chain carries a blend of all three signals
in one molecule. The point is not simply "more signal" — it is complementary signal:
three arms, each contributing a different strength, tuned to work together.
GLP-1 arm. Lifts insulin only when glucose is high — a built-in brake that keeps the risk of low blood sugar modest — and dials down appetite through the brain's fullness circuits.
GIP arm. Adds its own insulin-supporting and appetite effects and appears to improve how the body handles fat, complementing rather than duplicating the GLP-1 arm.
Glucagon arm. Raises energy expenditure and drives the liver to burn through stored fat — an accelerator that the two incretin arms hold in balance so the net effect stays favourable.
MECHANISM · ONE CHAIN · THREE LOCKS
2. Why one molecule can fit three receptors
The reason a single chain can address three receptors is a piece of deep biology. GLP-1, GIP
and glucagon are not strangers — they are evolutionary cousins, members of the
secretin–glucagon peptide superfamily2. GLP-1 and glucagon are
even cut from the very same precursor protein, proglucagon. And all three of their receptors
are class-B G-protein-coupled receptors3, a family that reads a
similar molecular grammar at the cell surface.
That shared ancestry is the engineering opening. If three locks are variations on one design,
a well-shaped master key can turn all of them. Peptide designers build a chimeric sequence —
a hybrid backbone that borrows features from each hormone — so that a single molecule is recognised
by all three receptors. The craft is in the balance: how strongly the chain pulls at each
receptor, and how long it lasts in the blood, are written into the sequence itself.
Three hormones, one family, one backbone — the tri-agonist is a master key cut to fit related locks.
3. Why three arms advance metabolic care
The field arrived here in steps, and each step widened the benefit. First came single-receptor
GLP-1 agonists. Then dual GIP + GLP-1 agonism — one chain, two incretin receptors —
reached further on glucose and body weight than the GLP-1 arm alone. The triple agonist adds
the glucagon arm on top, recruiting energy expenditure and liver-fat clearance into the same
molecule4. The lead example studied in this class is
retatrutide (development code LY3437943), a GLP-1 / GIP / glucagon agonist reported in
mid-stage obesity and type 2 diabetes trials — the reference point most triple agonists are
now measured against. It is not alone: efocipegtrutide (HM15211), another engineered
GLP-1 / GIP / glucagon tri-agonist, has been studied for fatty-liver disease, and the wider field
is populated by a growing ladder of dual and triple designs. These named molecules are the concrete
face of the concept — single chains, three receptor arms, one balanced backbone.
An illustrative agonist ladder (mono → dual → triple)
Generation
Receptors engaged
What each step adds
Mono
GLP-1
Glucose-dependent insulin + appetite restraint in one arm
Dual
GIP + GLP-1
A second incretin arm — further glucose and weight effect
Triple
GLP-1 + GIP + glucagon
Adds energy expenditure and liver-fat mobilisation
The ladder above is illustrative of the concept, not a head-to-head comparison of
named products or outcomes. Individual molecules differ, and results remain under active
investigation.
Read benefit-first, the appeal is straightforward: obesity and type 2 diabetes are
treatable metabolic conditions, and a molecule that engages three complementary levers can shape
how weight is lost and how the liver and glucose respond — not merely how much. That is the
case for three receptors at once.
THE OPEN FRONTIER · BALANCE
4. The frontier — balancing three potencies in one sequence
The hard part of a triple agonist is not adding a third receptor; it is tuning the three
arms against each other. Because the glucagon arm can raise glucose on its own, its pull has to be
set carefully relative to the two insulin-supporting incretin arms, so the whole molecule reads as
a net benefit. Every triple agonist is, in effect, a solution to a three-way balance problem —
relative potency at each receptor, plus how long the chain survives in circulation — all encoded
into a single sequence.
There is a second, quieter frontier: these are fragile molecules. A longer, more
elaborate engineered chain has more residues that can oxidise, aggregate or slowly unfold if it is
handled, dried or stored carelessly. Designing the balance is one half of the work; carrying the
balanced molecule intact from synthesiser to dose is the other. That is exactly where preservation
science meets the class — from
TgShift, which lifts the collapse ceiling of a dried peptide →
to RedoxVault →.
5. The story — three cousins, one backbone
The triple agonist looks like a modern invention, but its foundation is an ancient family tie.
GLP-1, GIP and glucagon descend from a shared ancestral peptide in the
secretin–glucagon superfamily — GLP-1 and glucagon literally emerge from the same
proglucagon gene, snipped apart into hormones that push metabolism in different directions.
For decades this kinship was a curiosity of textbooks. Then designers realised it was an
opportunity: if the receptors are relatives, one chain might satisfy them all.
The first deliberate proof came in 2009, when a rationally designed GLP-1 / glucagon
co-agonist was shown to reduce body weight in rodents5 — a single
molecule intentionally engaging two members of the family at once. Six years later, the same line
of work produced a monomeric triple agonist hitting all three receptors together in
animals6, the concept that molecules such as retatrutide now carry into
human study. The tri-agonist is, at heart, a family reunion engineered on purpose: three related
hormones, spoken by one carefully balanced backbone.
Reading the family ties between GLP-1, GIP and glucagon was the work of patient
metabolic and peptide chemistry — the ground Triagon and Panacea Bio Chem stand on. By
Bogdan Dicoias.
6. Panacea Bio Chem's angle — Triagon
Panacea Bio Chem researches balanced multi-receptor peptide design, and Triagon is
the working name of its investigational interest in the triple receptor incretin agonist concept.
Where the difficulty of this class lies less in which receptors to engage than in
tuning three arms into one molecule and keeping that molecule intact from synthesiser
to dose, Panacea approaches a tri-agonist as a chain it can both design and protect — pairing
balanced sequence engineering with its own preservation platform.
The exact sequence, receptor-potency balance, formulation and characterisation data behind
Triagon are held as a proprietary Panacea Bio Chem programme, developed by Bogdan Dicoias —
an amino-acid-chain designer and founder who works largely out of view, and whose peptide and
preservation technologies have quietly drawn interest from across the pharmaceutical industry. His
work in the multi-agonist field is extensive: Panacea Bio Chem does not treat triple agonism as a
single molecule but as a whole range — a gama of balanced multi-receptor chains climbing
from dual and triple designs upward toward higher-order agonism. The outline of the work is public;
the specifics stay behind the door.
What can be said plainly is the stack around each chain. A Triagon-class peptide is designed,
dried, sealed and delivered with the same tools Panacea applies to every fragile molecule. The
sequence is engineered residue by residue as a
designer peptide →;
the dried cake is formed under
TgShift →
for a higher collapse ceiling, longer shelf-life and cleaner reconstitution, with
DiastolVAC™ shaping the vacuum-pulsation curve to the cake's own drying kinetics and
Cryolapse™ reading residual moisture — all orchestrated in real time by the
S3Pulse™ biointegrity engine →.
The finished chain is loaded as a Peptourbillon™ blend into a dual-chamber
Lyoprester® cartridge — argon-flushed cake above, matched P-EARLs™ aseptic
reconstitution liquid below — and dispensed through an EZnject™ pen that merges the two in a
single twist across a hundred indexed doses. Balanced design on one side, carried intact from
synthesiser to dose on the other.
The range, and its ceiling. Within Panacea's multi-agonist gama, the triple agonist is a
waypoint rather than the summit. Named at the top of the range is Pentatrutide — Panacea Bio
Chem's flagship, positioned as the best in the gama, where the balancing craft that a tri-agonist
demands is pushed further still. Triagon sits a rung below it on the same ladder: the same
discipline of tuning several receptor arms into one chain, and the same preservation platform
carrying that chain to the patient intact.
A triple agonist you can hold — exadipo3. The concept reaches a
real Panacea kit in exadipo3, a Peptourbillon pairing the triple agonist
retatrutide with oxytocin (12.2 mg), presented in a Lyoprester dual-chamber
cartridge and EZnject pen — the same stack described above, in product form.
This section describes an active research direction and a real product line, stated
truthfully. Nothing here is a therapeutic claim, and no efficacy or outcome for Triagon or
Pentatrutide is asserted.
7. Application fields — where three arms could reach furthest
Because the three receptors sit across many organs, the concept's reach may extend well beyond
its first uses. Directions under active scientific investigation include:
Metabolic core. Obesity and type 2 diabetes anchor the concept — the largest unmet burden, and where the glucose-and-weight case runs deepest.
Liver and energy. The glucagon arm's pull on liver fat and energy expenditure opens investigation into metabolic-associated fatty-liver disease and the composition of weight change.
Balance as a design target. The three-way potency ratio is itself a research field: tuning the arms for benefit while holding tolerability is where much of the creative work sits.
Delivery and stability. A larger tri-agonist chain raises the preservation bar — a storage-stable, long-acting form is the last-mile prize, and the sphere Panacea researches, where Triagon is aimed.
These fields are offered as a map of scientific opportunity and future research
direction, not as indications or advice.
THE CLASS TODAY · REGISTRY RECORD
Where the triple-agonist class stands — the registry record, checked 2026-09-05
The class has moved since the phase-2 reports cited below: all four large phase-3
TRIUMPH trials of the reference agent retatrutide (LY3437943) are now marked
completed in the public registry, with no results posted there at the date checked. A phase-3
head-to-head against the dual agonist tirzepatide is active, and a large outcomes trial
runs toward 2029. Earlier sections of this brief were written when the programme sat in
mid-stage trials; the dated record below is the registry state as retrieved on 2026-09-05.
Registry entries are sponsor-reported and change as results post; the figures
above are a dated reading, not a standing claim. Retatrutide and tirzepatide are named as the
class's public reference points and remain the products of their respective sponsors.
Is the third arm worth it?
The honest answer is: not yet established in humans. The extra effect of the
glucagon arm has not been isolated in a matched comparison against a dual agonist —
the figures in the ladder above come from separate trials. The phase-3 study built to answer
exactly this is the head-to-head of retatrutide against tirzepatide,
NCT06662383
(about 800 participants; completion expected December 2026). Until it reads out, the question
is open — and for the first time it is being measured directly.
Frequently asked
What is a triple receptor incretin agonist, in plain terms? A single engineered
peptide built to switch on three related hormone receptors at once — the GLP-1, GIP
and glucagon receptors. Because the three natural hormones are structural cousins, one
chain can be shaped to fit all three locks, so pressing them together aims to do more than any one
alone.
Why engage three receptors at once instead of one? Each arm brings a different
strength: GLP-1 lifts insulin only when glucose is high and eases appetite; GIP adds
insulin-sensitising and appetite effects; the glucagon arm raises energy expenditure and helps
mobilise liver fat. Combining three complementary arms in one balanced molecule is engineered to
widen the metabolic benefit.
How can one peptide fit three different receptors? GLP-1, GIP and glucagon belong to
the same secretin–glucagon peptide superfamily and all act through class-B G-protein-coupled
receptors; GLP-1 and glucagon are cut from the same proglucagon precursor. That shared ancestry
lets a carefully designed chimeric sequence address all three.
What is Triagon? Triagon is Panacea Bio Chem's working name for its
investigational interest in the triple receptor incretin agonist concept. Panacea researches
balanced multi-receptor peptide design; the specific sequence and data are proprietary to Bogdan
Dicoias. This page is about the science of the concept — nothing here is medical advice.
Trending in the field
Recent developments in the field — refreshed 2026-09-10 by Panacea Bio Chem.
